Prot #PCI-32765MCL4001: An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Winter, Jane Norma (PD/PI)

Medicine, Hematology Oncology Division

Project: Research project

Status	Finished
Effective start/end date	8/27/13 → 9/30/14

Funding

Quintiles, Inc. (Prot #PCI-32765MCL4001 // Prot #PCI-32765MCL4001)
Janssen Research & Development, LLC (Prot #PCI-32765MCL4001 // Prot #PCI-32765MCL4001)